{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:40Z","timestamp":1792427680765,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00134-024-07611-4","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T05:02:24Z","timestamp":1725944544000},"page":"1791-1803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Complement system activation: bridging physiology, pathophysiology, and therapy"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-1508","authenticated-orcid":false,"given":"Elie","family":"Azoulay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Aziz","family":"Bousfiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Essafti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djillali","family":"Annane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"7611_CR1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement: first of two parts. N Engl J Med 344:1058\u20131066. https:\/\/doi.org\/10.1056\/NEJM200104053441406","journal-title":"N Engl J Med"},{"key":"7611_CR2","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement: second of two parts. N Engl J Med 344:1140\u20131144. https:\/\/doi.org\/10.1056\/NEJM200104123441506","journal-title":"N Engl J Med"},{"key":"7611_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101640","volume":"60","author":"M Mannes","year":"2022","unstructured":"Mannes M, Mastellos DC, Ekdahl KN et al (2022) Complement C3 activation in the ICU: disease and therapy as Bonnie and Clyde. Semin Immunol 60:101640. https:\/\/doi.org\/10.1016\/j.smim.2022.101640","journal-title":"Semin Immunol"},{"key":"7611_CR4","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","volume":"125","author":"R Cofiell","year":"2015","unstructured":"Cofiell R, Kukreja A, Bedard K et al (2015) Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125:3253\u20133262. https:\/\/doi.org\/10.1182\/blood-2014-09-600411","journal-title":"Blood"},{"key":"7611_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.811504","volume":"9","author":"M Blasco","year":"2022","unstructured":"Blasco M, Guill\u00e9n-Olmos E, Diaz-Ricart M, Palomo M (2022) Complement mediated endothelial damage in thrombotic microangiopathies. Front Med 9:811504. https:\/\/doi.org\/10.3389\/fmed.2022.811504","journal-title":"Front Med"},{"key":"7611_CR6","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/ASN.2019040331","volume":"30","author":"J Zuber","year":"2019","unstructured":"Zuber J, Frimat M, Caillard S et al (2019) Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol JASN 30:2449\u20132463. https:\/\/doi.org\/10.1681\/ASN.2019040331","journal-title":"J Am Soc Nephrol JASN"},{"key":"7611_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200057","volume":"10","author":"K Iwasa","year":"2023","unstructured":"Iwasa K, Furukawa Y, Yoshikawa H et al (2023) CD59 expression in skeletal muscles and its role in myasthenia gravis. Neurol Neuroimmunol Neuroinflammation 10:e200057. https:\/\/doi.org\/10.1212\/NXI.0000000000200057","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"7611_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000348639","volume":"181","author":"JJ Weening","year":"2013","unstructured":"Weening JJ, Ronco P, Remuzzi G (2013) Advances in the pathology of glomerular diseases. Contrib Nephrol 181:12\u201321. https:\/\/doi.org\/10.1159\/000348639","journal-title":"Contrib Nephrol"},{"key":"7611_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.seminhematol.2022.01.001","volume":"59","author":"R Peffault de Latour","year":"2022","unstructured":"Peffault de Latour R, Hosokawa K, Risitano AM (2022) Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. Semin Hematol 59:38\u201346. https:\/\/doi.org\/10.1053\/j.seminhematol.2022.01.001","journal-title":"Semin Hematol"},{"key":"7611_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I et al (2021) Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 384:1028\u20131037. https:\/\/doi.org\/10.1056\/NEJMoa2029073","journal-title":"N Engl J Med"},{"key":"7611_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614\u2013625. https:\/\/doi.org\/10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"key":"7611_CR12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical haemolytic: uremic syndrome. N Engl J Med 368:2169\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"key":"7611_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0002-9343(89)90224-6","volume":"86","author":"CE Hack","year":"1989","unstructured":"Hack CE, Nuijens JH, Felt-Bersma RJ et al (1989) Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 86:20\u201326. https:\/\/doi.org\/10.1016\/0002-9343(89)90224-6","journal-title":"Am J Med"},{"key":"7611_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1553-2712.2010.00713.x","volume":"17","author":"JG Younger","year":"2010","unstructured":"Younger JG, Bracho DO, Chung-Esaki HM et al (2010) Complement activation in emergency department patients with severe sepsis. Acad Emerg Med Off J Soc Acad Emerg Med 17:353\u2013359. https:\/\/doi.org\/10.1111\/j.1553-2712.2010.00713.x","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med"},{"key":"7611_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.it.2007.02.006","volume":"28","author":"MM Markiewski","year":"2007","unstructured":"Markiewski MM, Nilsson B, Ekdahl KN et al (2007) Complement and coagulation: strangers or partners in crime? Trends Immunol 28:184\u2013192. https:\/\/doi.org\/10.1016\/j.it.2007.02.006","journal-title":"Trends Immunol"},{"key":"7611_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13028","volume":"48","author":"AJT Wood","year":"2018","unstructured":"Wood AJT, Vassallo A, Summers C et al (2018) C5a anaphylatoxin and its role in critical illness-induced organ dysfunction. Eur J Clin Invest 48:e13028. https:\/\/doi.org\/10.1111\/eci.13028","journal-title":"Eur J Clin Invest"},{"key":"7611_CR17","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood.2020007208","volume":"139","author":"NI Popescu","year":"2022","unstructured":"Popescu NI, Lupu C, Lupu F (2022) Disseminated intravascular coagulation and its immune mechanisms. Blood 139:1973\u20131986. https:\/\/doi.org\/10.1182\/blood.2020007208","journal-title":"Blood"},{"key":"7611_CR18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.4049\/jimmunol.166.2.1193","volume":"166","author":"M Huber-Lang","year":"2001","unstructured":"Huber-Lang M, Sarma VJ, Lu KT et al (2001) Role of C5a in multiorgan failure during sepsis. J Immunol Baltim Md 1950 166:1193\u20131199. https:\/\/doi.org\/10.4049\/jimmunol.166.2.1193","journal-title":"J Immunol Baltim Md 1950"},{"key":"7611_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/407324","volume":"2012","author":"J Charchaflieh","year":"2012","unstructured":"Charchaflieh J, Wei J, Labaze G et al (2012) The role of complement system in septic shock. Clin Dev Immunol 2012:407324. https:\/\/doi.org\/10.1155\/2012\/407324","journal-title":"Clin Dev Immunol"},{"key":"7611_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40560-018-0309-5","volume":"6","author":"T Hirose","year":"2018","unstructured":"Hirose T, Ogura H, Takahashi H et al (2018) Serial change of C1 inhibitor in patients with sepsis: a prospective observational study. J Intensive Care 6:37. https:\/\/doi.org\/10.1186\/s40560-018-0309-5","journal-title":"J Intensive Care"},{"key":"7611_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/CCM.0b013e318236edb8","volume":"40","author":"AA Igonin","year":"2012","unstructured":"Igonin AA, Protsenko DN, Galstyan GM et al (2012) C1-esterase inhibitor infusion increases survival rates for patients with sepsis*. Crit Care Med 40:770\u2013777. https:\/\/doi.org\/10.1097\/CCM.0b013e318236edb8","journal-title":"Crit Care Med"},{"key":"7611_CR22","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1097\/CCM.0b013e318258eb7a","volume":"40","author":"LJ Schlapbach","year":"2012","unstructured":"Schlapbach LJ, Schibler A, Jensenius JC (2012) C1-esterase inhibitor treatment in sepsis-can we target the right patients? Crit Care Med 40:2735\u20132737. https:\/\/doi.org\/10.1097\/CCM.0b013e318258eb7a","journal-title":"Crit Care Med"},{"key":"7611_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1182\/blood-2010-02-269746","volume":"116","author":"R Silasi-Mansat","year":"2010","unstructured":"Silasi-Mansat R, Zhu H, Popescu NI et al (2010) Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116:1002\u20131010. https:\/\/doi.org\/10.1182\/blood-2010-02-269746","journal-title":"Blood"},{"key":"7611_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1164\/rccm.201910-2083OC","volume":"202","author":"W Bain","year":"2020","unstructured":"Bain W, Li H, van der Geest R et al (2020) Increased alternative complement pathway function and improved survival during critical illness. Am J Respir Crit Care Med 202:230\u2013240. https:\/\/doi.org\/10.1164\/rccm.201910-2083OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7611_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1164\/rccm.202005-1926ED","volume":"202","author":"M Bosmann","year":"2020","unstructured":"Bosmann M (2020) Complement activation during critical illness: current findings and an outlook in the era of COVID-19. Am J Respir Crit Care Med 202:163\u2013165. https:\/\/doi.org\/10.1164\/rccm.202005-1926ED","journal-title":"Am J Respir Crit Care Med"},{"key":"7611_CR26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/CCM.0000000000000275","volume":"42","author":"AP Pietropaoli","year":"2014","unstructured":"Pietropaoli AP, Wexler O (2014) RBC dysfunction in critical illness: driven by complement? Crit Care Med 42:1323\u20131324. https:\/\/doi.org\/10.1097\/CCM.0000000000000275","journal-title":"Crit Care Med"},{"key":"7611_CR27","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1097\/CCM.0000000000000231","volume":"42","author":"T Muroya","year":"2014","unstructured":"Muroya T, Kannan L, Ghiran IC et al (2014) C4d deposits on the surface of RBCs in trauma patients and interferes with their function. Crit Care Med 42:e364-372. https:\/\/doi.org\/10.1097\/CCM.0000000000000231","journal-title":"Crit Care Med"},{"key":"7611_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/s0140-6736(80)91403-8","volume":"1","author":"DE Hammerschmidt","year":"1980","unstructured":"Hammerschmidt DE, Weaver LJ, Hudson LD et al (1980) Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome: pathophysiological relevance and possible prognostic value. Lancet Lond Engl 1:947\u2013949. https:\/\/doi.org\/10.1016\/s0140-6736(80)91403-8","journal-title":"Lancet Lond Engl"},{"key":"7611_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1172\/JCI118818","volume":"98","author":"MS Mulligan","year":"1996","unstructured":"Mulligan MS, Schmid E, Beck-Schimmer B et al (1996) Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 98:503\u2013512. https:\/\/doi.org\/10.1172\/JCI118818","journal-title":"J Clin Invest"},{"key":"7611_CR30","doi-asserted-by":"publisher","first-page":"7664","DOI":"10.4049\/jimmunol.180.11.7664","volume":"180","author":"D Rittirsch","year":"2008","unstructured":"Rittirsch D, Flierl MA, Day DE et al (2008) Acute lung injury induced by lipopolysaccharide is independent of complement activation. J Immunol Baltim Md 1950 180:7664\u20137672. https:\/\/doi.org\/10.4049\/jimmunol.180.11.7664","journal-title":"J Immunol Baltim Md 1950"},{"key":"7611_CR31","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3324\/haematol.2020.260117","volume":"105","author":"R Peffault de Latour","year":"2020","unstructured":"Peffault de Latour R, Bergeron A, Lengline E et al (2020) Complement C5 inhibition in patients with COVID-19 - a promising target? Haematologica 105:2847\u20132850. https:\/\/doi.org\/10.3324\/haematol.2020.260117","journal-title":"Haematologica"},{"key":"7611_CR32","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.4049\/jimmunol.2000644","volume":"205","author":"MW Lo","year":"2020","unstructured":"Lo MW, Kemper C, Woodruff TM (2020) COVID-19: complement, coagulation, and collateral damage. J Immunol Baltim Md 205:1488\u20131495. https:\/\/doi.org\/10.4049\/jimmunol.2000644","journal-title":"J Immunol Baltim Md"},{"key":"7611_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/CH-151993","volume":"61","author":"H Helling","year":"2015","unstructured":"Helling H, Stephan B, Pindur G (2015) Coagulation and complement system in critically ill patients. Clin Hemorheol Microcirc 61:185\u2013193. https:\/\/doi.org\/10.3233\/CH-151993","journal-title":"Clin Hemorheol Microcirc"},{"key":"7611_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714511","volume":"12","author":"YM Ali","year":"2021","unstructured":"Ali YM, Ferrari M, Lynch NJ et al (2021) Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol 12:714511. https:\/\/doi.org\/10.3389\/fimmu.2021.714511","journal-title":"Front Immunol"},{"key":"7611_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100590","volume":"28","author":"D Annane","year":"2020","unstructured":"Annane D, Heming N, Grimaldi-Bensouda L et al (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 28:100590. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100590","journal-title":"EClinicalMedicine"},{"key":"7611_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742446","volume":"12","author":"F Defendi","year":"2021","unstructured":"Defendi F, Leroy C, Epaulard O et al (2021) Complement alternative and mannose-binding lectin pathway activation is associated with COVID-19 mortality. Front Immunol 12:742446. https:\/\/doi.org\/10.3389\/fimmu.2021.742446","journal-title":"Front Immunol"},{"key":"7611_CR37","doi-asserted-by":"publisher","first-page":"25018","DOI":"10.1073\/pnas.2010540117","volume":"117","author":"JC Holter","year":"2020","unstructured":"Holter JC, Pischke SE, de Boer E et al (2020) Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A 117:25018\u201325025. https:\/\/doi.org\/10.1073\/pnas.2010540117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7611_CR38","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","volume":"26","author":"V Ramlall","year":"2020","unstructured":"Ramlall V, Thangaraj PM, Meydan C et al (2020) Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med 26:1609\u20131615. https:\/\/doi.org\/10.1038\/s41591-020-1021-2","journal-title":"Nat Med"},{"key":"7611_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13054-023-04344-6","volume":"27","author":"AH de Nooijer","year":"2023","unstructured":"de Nooijer AH, Kotsaki A, Kranidioti E et al (2023) Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity. Crit Care Lond Engl 27:63. https:\/\/doi.org\/10.1186\/s13054-023-04344-6","journal-title":"Crit Care Lond Engl"},{"key":"7611_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo2341","volume":"8","author":"P Skendros","year":"2022","unstructured":"Skendros P, Germanidis G, Mastellos DC et al (2022) Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. Sci Adv 8:eabo2341. https:\/\/doi.org\/10.1126\/sciadv.abo2341","journal-title":"Sci Adv"},{"key":"7611_CR41","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S2213-2600(23)00082-6","volume":"11","author":"D Annane","year":"2023","unstructured":"Annane D, Pittock SJ, Kulkarni HS et al (2023) Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir Med 11:1051\u20131063. https:\/\/doi.org\/10.1016\/S2213-2600(23)00082-6","journal-title":"Lancet Respir Med"},{"key":"7611_CR42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/CCM.0000000000002281","volume":"45","author":"D LoVerde","year":"2017","unstructured":"LoVerde D, Files DC, Krishnaswamy G (2017) Angioedema. Crit Care Med 45:725\u2013735. https:\/\/doi.org\/10.1097\/CCM.0000000000002281","journal-title":"Crit Care Med"},{"key":"7611_CR43","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.3390\/jcm9113402","volume":"9","author":"G Loules","year":"2020","unstructured":"Loules G, Parsopoulou F, Zamanakou M et al (2020) Deciphering the genetics of primary angioedema with normal levels of C1 inhibitor. J Clin Med 9:3402. https:\/\/doi.org\/10.3390\/jcm9113402","journal-title":"J Clin Med"},{"key":"7611_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2500\/ajra.2011.25.3661","volume":"25","author":"BL Zuraw","year":"2011","unstructured":"Zuraw BL, Christiansen SC (2011) Pathophysiology of hereditary angioedema. Am J Rhinol Allergy 25:373\u2013378. https:\/\/doi.org\/10.2500\/ajra.2011.25.3661","journal-title":"Am J Rhinol Allergy"},{"key":"7611_CR45","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S et al (2022) The international WAO\/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update. Allergy 77:1961\u20131990. https:\/\/doi.org\/10.1111\/all.15214","journal-title":"Allergy"},{"key":"7611_CR46","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1742-1241.2005.00352.x","volume":"59","author":"HJ Longhurst","year":"2005","unstructured":"Longhurst HJ (2005) Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract 59:594\u2013599. https:\/\/doi.org\/10.1111\/j.1742-1241.2005.00352.x","journal-title":"Int J Clin Pract"},{"key":"7611_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-023-03630-x","volume":"118","author":"J-I Nishimura","year":"2023","unstructured":"Nishimura J-I, Kawaguchi T, Ito S et al (2023) Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol 118:419\u2013431. https:\/\/doi.org\/10.1007\/s12185-023-03630-x","journal-title":"Int J Hematol"},{"key":"7611_CR48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi M-P, Marantz JL et al (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790","journal-title":"Br J Haematol"},{"key":"7611_CR49","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid 1:EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"key":"7611_CR50","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","volume":"270","author":"A Meisel","year":"2023","unstructured":"Meisel A, Annane D, Vu T et al (2023) Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 270:3862\u20133875. https:\/\/doi.org\/10.1007\/s00415-023-11699-x","journal-title":"J Neurol"},{"key":"7611_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/mus.27742","volume":"67","author":"M Benatar","year":"2023","unstructured":"Benatar M, Cutter G, Kaminski HJ (2023) The best and worst of times in therapy development for myasthenia gravis. Muscle Nerve 67:12\u201316. https:\/\/doi.org\/10.1002\/mus.27742","journal-title":"Muscle Nerve"},{"key":"7611_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22:395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"key":"7611_CR53","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1182\/bloodadvances.2016002832","volume":"1","author":"THJ Goodship","year":"2017","unstructured":"Goodship THJ, Pinto F, Weston-Davies WH et al (2017) Use of the complement inhibitor coversin to treat HSCT-associated TMA. Blood Adv 1:1254\u20131258. https:\/\/doi.org\/10.1182\/bloodadvances.2016002832","journal-title":"Blood Adv"},{"key":"7611_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M (2024) Zilucoplan: first approval. Drugs 84:99\u2013104. https:\/\/doi.org\/10.1007\/s40265-023-01977-3","journal-title":"Drugs"},{"key":"7611_CR55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molimm.2009.08.032","volume":"47","author":"H Qu","year":"2009","unstructured":"Qu H, Ricklin D, Lambris JD (2009) Recent developments in low molecular weight complement inhibitors. Mol Immunol 47:185\u2013195. https:\/\/doi.org\/10.1016\/j.molimm.2009.08.032","journal-title":"Mol Immunol"},{"key":"7611_CR56","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet Lond Engl 390:681\u2013696. https:\/\/doi.org\/10.1016\/S0140-6736(17)30062-4","journal-title":"Lancet Lond Engl"},{"key":"7611_CR57","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","volume":"129","author":"TS Jokiranta","year":"2017","unstructured":"Jokiranta TS (2017) HUS and atypical HUS. Blood 129:2847\u20132856. https:\/\/doi.org\/10.1182\/blood-2016-11-709865","journal-title":"Blood"},{"issue":"Suppl 4","key":"7611_CR58","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1002\/ajh.26854","volume":"98","author":"J Leon","year":"2023","unstructured":"Leon J, LeStang M-B, Sberro-Soussan R et al (2023) Complement-driven hemolytic uremic syndrome. Am J Hematol 98(Suppl 4):S44\u2013S56. https:\/\/doi.org\/10.1002\/ajh.26854","journal-title":"Am J Hematol"},{"key":"7611_CR59","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1084\/jem.20070301","volume":"204","author":"MC Pickering","year":"2007","unstructured":"Pickering MC, de Jorge EG, Martinez-Barricarte R et al (2007) Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204:1249\u20131256. https:\/\/doi.org\/10.1084\/jem.20070301","journal-title":"J Exp Med"},{"key":"7611_CR60","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/ASN.2018070759","volume":"29","author":"F Bu","year":"2018","unstructured":"Bu F, Zhang Y, Wang K et al (2018) Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol JASN 29:2809\u20132819. https:\/\/doi.org\/10.1681\/ASN.2018070759","journal-title":"J Am Soc Nephrol JASN"},{"key":"7611_CR61","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol CJASN 8:554\u2013562. https:\/\/doi.org\/10.2215\/CJN.04760512","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"7611_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0030041","volume":"3","author":"PF Zipfel","year":"2007","unstructured":"Zipfel PF, Edey M, Heinen S et al (2007) Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 3:e41. https:\/\/doi.org\/10.1371\/journal.pgen.0030041","journal-title":"PLoS Genet"},{"key":"7611_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.10.009","author":"LM Palma","year":"2021","unstructured":"Palma LM, Sridharan M, Sethi S (2021) Complement in secondary thrombotic microangiopathy. Kidney Int Rep. https:\/\/doi.org\/10.1016\/j.ekir.2020.10.009","journal-title":"Kidney Int Rep"},{"key":"7611_CR64","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.chest.2017.03.055","volume":"152","author":"E Azoulay","year":"2017","unstructured":"Azoulay E, Knoebl P, Garnacho-Montero J et al (2017) Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest 152:424\u2013434. https:\/\/doi.org\/10.1016\/j.chest.2017.03.055","journal-title":"Chest"},{"key":"7611_CR65","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1007\/s00134-019-05736-5","volume":"45","author":"E Azoulay","year":"2019","unstructured":"Azoulay E, Bauer PR, Mariotte E et al (2019) Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med 45:1518\u20131539. https:\/\/doi.org\/10.1007\/s00134-019-05736-5","journal-title":"Intensive Care Med"},{"key":"7611_CR66","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol CJASN 5:1844\u20131859. https:\/\/doi.org\/10.2215\/CJN.02210310","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"7611_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00424-4","author":"FF Fakhouri","year":"2021","unstructured":"Fakhouri FF, Fr\u00e9meaux-Bacchi V (2021) Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. https:\/\/doi.org\/10.1038\/s41581-021-00424-4","journal-title":"Nat Rev Nephrol"},{"key":"7611_CR68","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood.2020005221","volume":"136","author":"F Fakhouri","year":"2020","unstructured":"Fakhouri F, Scully M, Prov\u00f4t F et al (2020) Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood 136:2103\u20132117. https:\/\/doi.org\/10.1182\/blood.2020005221","journal-title":"Blood"},{"key":"7611_CR69","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2215\/CJN.00280117","volume":"12","author":"A Bruel","year":"2017","unstructured":"Bruel A, Kavanagh D, Noris M et al (2017) Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol CJASN 12:1237\u20131247. https:\/\/doi.org\/10.2215\/CJN.00280117","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"7611_CR70","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016090995","author":"M Gaggl","year":"2018","unstructured":"Gaggl M, Aigner C, Csuka D et al (2018) Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol JASN. https:\/\/doi.org\/10.1681\/ASN.2016090995","journal-title":"J Am Soc Nephrol JASN"},{"issue":"75","key":"7611_CR71","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","volume":"1979","author":"SAMEG Timmermans","year":"2020","unstructured":"Timmermans SAMEG, W\u00e9rion A, Damoiseaux JGMC et al (2020) Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy. Hypertens Dallas Tex 1979(75):422\u2013430. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13714","journal-title":"Hypertens Dallas Tex"},{"key":"7611_CR72","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","volume":"96","author":"T Cavero","year":"2019","unstructured":"Cavero T, Arjona E, Soto K et al (2019) Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney Int 96:995\u20131004. https:\/\/doi.org\/10.1016\/j.kint.2019.05.014","journal-title":"Kidney Int"},{"key":"7611_CR73","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMicm2109500","volume":"385","author":"F Poli","year":"2021","unstructured":"Poli F, Yusuf IH (2021) Retinopathy in malignant hypertension. N Engl J Med 385:1994. https:\/\/doi.org\/10.1056\/NEJMicm2109500","journal-title":"N Engl J Med"},{"key":"7611_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012862.pub2","volume":"3","author":"D Pugh","year":"2021","unstructured":"Pugh D, O\u2019Sullivan ED, Duthie FA et al (2021) Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 3:CD012862. https:\/\/doi.org\/10.1002\/14651858.CD012862.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7611_CR75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM et al (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis Off J Natl Kidney Found 68:84\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"7611_CR76","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G et al (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026","journal-title":"Kidney Int"},{"key":"7611_CR77","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P et al (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073. https:\/\/doi.org\/10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"7611_CR78","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G et al (2020) The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int 97:1287\u20131296. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035","journal-title":"Kidney Int"},{"key":"7611_CR79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/0886022X.2018.1427110","volume":"40","author":"AA Mukherjee","year":"2018","unstructured":"Mukherjee AA, Kandhare AD, Bodhankar SL (2018) Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO. Ren Fail 40:107\u2013118. https:\/\/doi.org\/10.1080\/0886022X.2018.1427110","journal-title":"Ren Fail"},{"key":"7611_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2023.154283","volume":"76","author":"E Azoulay","year":"2023","unstructured":"Azoulay E, Souppart V, Kentish-Barnes N et al (2023) Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome. J Crit Care 76:154283. https:\/\/doi.org\/10.1016\/j.jcrc.2023.154283","journal-title":"J Crit Care"},{"key":"7611_CR81","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, Le Quintrec M, Krid S et al (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 12:3337\u20133354. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04252.x","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"7611_CR82","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","volume":"65","author":"F Bu","year":"2015","unstructured":"Bu F, Meyer NC, Zhang Y et al (2015) Soluble c5b\u20139 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis Off J Natl Kidney Found 65:968\u2013969. https:\/\/doi.org\/10.1053\/j.ajkd.2015.02.326","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"7611_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","volume":"74","author":"M Galbusera","year":"2019","unstructured":"Galbusera M, Noris M, Gastoldi S et al (2019) An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome. Am J Kidney Dis Off J Natl Kidney Found 74:56\u201372. https:\/\/doi.org\/10.1053\/j.ajkd.2018.11.012","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"7611_CR84","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood.2022015583","volume":"141","author":"A Doreille","year":"2023","unstructured":"Doreille A, Rafat C, Rondeau E, Mesnard L (2023) How I treat thrombotic microangiopathy in the era of rapid genomics. Blood 141:147\u2013155. https:\/\/doi.org\/10.1182\/blood.2022015583","journal-title":"Blood"},{"key":"7611_CR85","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMc2100365","volume":"384","author":"MJ Owen","year":"2021","unstructured":"Owen MJ, Niemi A-K, Dimmock DP et al (2021) Rapid sequencing-based diagnosis of thiamine metabolism dysfunction syndrome. N Engl J Med 384:2159\u20132161. https:\/\/doi.org\/10.1056\/NEJMc2100365","journal-title":"N Engl J Med"},{"key":"7611_CR86","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"7611_CR87","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/NDT.S8915","volume":"7","author":"R Mantegazza","year":"2011","unstructured":"Mantegazza R, Bonanno S, Camera G, Antozzi C (2011) Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat 7:151\u2013160. https:\/\/doi.org\/10.2147\/NDT.S8915","journal-title":"Neuropsychiatr Dis Treat"},{"key":"7611_CR88","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P et al (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263:1473\u20131494. https:\/\/doi.org\/10.1007\/s00415-016-8045-z","journal-title":"J Neurol"},{"key":"7611_CR89","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475\u2013490. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"7611_CR90","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","volume":"259","author":"A Pevzner","year":"2012","unstructured":"Pevzner A, Schoser B, Peters K et al (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259:427\u2013435. https:\/\/doi.org\/10.1007\/s00415-011-6194-7","journal-title":"J Neurol"},{"issue":"1","key":"7611_CR91","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"7611_CR92","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molimm.2022proinf.08.018","volume":"151","author":"NSR Sanderson","year":"2022","unstructured":"Sanderson NSR (2022) Complement and myasthenia gravis. Mol Immunol 151:11\u201318. https:\/\/doi.org\/10.1016\/j.molimm.2022proinf.08.018","journal-title":"Mol Immunol"},{"key":"7611_CR93","doi-asserted-by":"publisher","first-page":"7","DOI":"10.11477\/mf.1416202551","volume":"76","author":"H Murai","year":"2024","unstructured":"Murai H (2024) The Japanese clinical guidelines 2022 for myasthenia gravis and lambert-eaton myasthenic syndrome: an overview. Brain Nerve Shinkei Kenkyu No Shinpo 76:7\u201312. https:\/\/doi.org\/10.11477\/mf.1416202551","journal-title":"Brain Nerve Shinkei Kenkyu No Shinpo"},{"key":"7611_CR94","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-024-07611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-024-07611-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-024-07611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:06:10Z","timestamp":1730862370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-024-07611-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":94,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7611"],"URL":"https:\/\/doi.org\/10.1007\/s00134-024-07611-4","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EA has received fees for lectures from Alexion, Sanofi, Gilead, and Pfizer. DA has received fees for lectures or to sit on advisory board from Alexion. JZ has received lecture fees, travel grants, and board member honorarium from Alexion Pharmaceuticals. AAB, YL, YT, SL, and ME report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}